Apogee Therapeutics is in the late innings of an independent life as a public company, and the equity is now best understood as a clean, near-cash deal arb on the pending all-cash sale to AbbVie announced on June 2, 2026. The headline number, $135.11 per share in cash for a total equity value of approximately $10.9 billion, is the load-bearing observation of this report. The deal, expected to close in the third quarter of 2026, subject to shareholder and regulatory approvals, prices Apogee at roughly a 100% premium to the unaffected share price in the days preceding the announcement, and it converts what was a high-burn, pre-commercial immunology biotech into a binary spread between the announced price and the price at which the equity actually trades.
The thesis for the next ninety days is no longer clinical. It is structural. The Phase 2 APEX Part B readout in May 2026, which delivered 65.9% EASI-75 at the mid-dose on the 16-week induction endpoint in moderate-to-severe atopic dermatitis, was the catalyst that brought AbbVie to the table, and the May 26, 2026 Blackstone Life Sciences revenue-participation agreement, which provides up to $1.3 billion in non-dilutive capital, is the financing layer that gave the buyer a pre-funded, de-risked asset. The pipeline, anchored by zumilokibart (APG777), a half-life-extended anti-IL-13 antibody, plus combinations APG279 and APG273, has been validated in the most market-meaningful way possible: a strategic acquirer paid 10.9 billion dollars in equity value, roughly the entire current market capitalization of the equity, for the privilege of owning it.
The single load-bearing risk is deal break. The transaction carries a customary termination fee, but if antitrust review of AbbVie's immunology franchise, currently dominated by Dupixent, takes longer than the announced third-quarter close, or if the proxy fails to clear a sufficient majority, the equity would re-rate to a clinical-asset valuation rather than the deal price. The next data point that tests the thesis is the special-meeting vote, followed by the regulatory clearance. Until those two clocks expire, the equity is a deal arb, not a biotech.